R&D

Reform in China’s Pharmaceuticals Sector - What the Doctor Ordered?

Reform in China’s Pharmaceuticals Sector - What the Doctor Ordered?

Fewer restrictions on drug pricing and greater access for foreign companies may make for a healthier China, and bring both potential growth and growing pains to the pharmaceutical industry—a sector analysts expect to be worth upwards of $300 billion by 2020.

Tags

R&D

R&D How-To: Managing IP, HR Concerns in China

R&D How-To: Managing IP, HR Concerns in China

More and more US companies have active research and development (R&D) operations in China, and many have seen these operations evolve from small groups primarily focused on product localization to globally significant operations conducting cutting-edge R&D for the China market. In a 2013 KPMG report, for example, an estimate was given for over 1,300 R&D multinational-operated R&D centers in China, a number that has likely risen since then.

Tags

R&D
IP
HR
Subscribe to RSS - R&D